Global Cancer Tumor Profiling Market Size, Status and Forecast 2019-2025

2 Global Cancer Tumor Profiling Quarterly Market Size Analysis

• 2.1 Cancer Tumor Profiling Business Impact Assessment - COVID-19
  • 2.1.1 Global Cancer Tumor Profiling Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cancer Tumor Profiling Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Cancer Tumor Profiling Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Cancer Tumor Profiling Headquarters and Area Served
• 3.3 Date of Key Players Enter into Cancer Tumor Profiling Market
• 3.4 Key Players Cancer Tumor Profiling Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cancer Tumor Profiling Segments, By Type

• 4.1 Introduction
  • 1.4.1 Next-generation Sequencing (NGS)
  • 1.4.2 Polymerase Chain Reaction (PCR)
  • 1.4.3 Immunohistochemistry (IHC)
  • 1.4.4 In Situ Hybridization (ISH)
  • 1.4.5 Microarray
  • 1.4.6 Others
• 4.2 By Type, Global Cancer Tumor Profiling Market Size, 2019-2021

5 Impact of Covid-19 on Cancer Tumor Profiling Segments, By Application

• 5.1 Overview
  • 5.5.1 Personalized Medicine
  • 5.5.2 Diagnostics
  • 5.5.3 Biomarker Discovery
  • 5.5.4 Prognostics
  • 5.5.5 Research Applications
• 5.2 By Application, Global Cancer Tumor Profiling Market Size, 2019-2021
  • 5.2.1 By Application, Global Cancer Tumor Profiling Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Qiagen N.V.
  • 7.1.1 Qiagen N.V. Business Overview
  • 7.1.2 Qiagen N.V. Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.1.3 Qiagen N.V. Cancer Tumor Profiling Product Introduction
  • 7.1.4 Qiagen N.V. Response to COVID-19 and Related Developments
• 7.2 Roche Molecular Systems Inc.
  • 7.2.1 Roche Molecular Systems Inc. Business Overview
  • 7.2.2 Roche Molecular Systems Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.2.3 Roche Molecular Systems Inc. Cancer Tumor Profiling Product Introduction
  • 7.2.4 Roche Molecular Systems Inc. Response to COVID-19 and Related Developments
• 7.3 Abott Molecular
  • 7.3.1 Abott Molecular Business Overview
  • 7.3.2 Abott Molecular Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.3.3 Abott Molecular Cancer Tumor Profiling Product Introduction
  • 7.3.4 Abott Molecular Response to COVID-19 and Related Developments
• 7.4 Illumina Inc.
  • 7.4.1 Illumina Inc. Business Overview
  • 7.4.2 Illumina Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.4.3 Illumina Inc. Cancer Tumor Profiling Product Introduction
  • 7.4.4 Illumina Inc. Response to COVID-19 and Related Developments
• 7.5 NeoGenomics Laboratories
  • 7.5.1 NeoGenomics Laboratories Business Overview
  • 7.5.2 NeoGenomics Laboratories Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.5.3 NeoGenomics Laboratories Cancer Tumor Profiling Product Introduction
  • 7.5.4 NeoGenomics Laboratories Response to COVID-19 and Related Developments
• 7.6 HTG Molecular Diagnostic
  • 7.6.1 HTG Molecular Diagnostic Business Overview
  • 7.6.2 HTG Molecular Diagnostic Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.6.3 HTG Molecular Diagnostic Cancer Tumor Profiling Product Introduction
  • 7.6.4 HTG Molecular Diagnostic Response to COVID-19 and Related Developments
• 7.7 Genomic Health Inc.
  • 7.7.1 Genomic Health Inc. Business Overview
  • 7.7.2 Genomic Health Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.7.3 Genomic Health Inc. Cancer Tumor Profiling Product Introduction
  • 7.7.4 Genomic Health Inc. Response to COVID-19 and Related Developments
• 7.8 Hologic Gen-Probe
  • 7.8.1 Hologic Gen-Probe Business Overview
  • 7.8.2 Hologic Gen-Probe Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.8.3 Hologic Gen-Probe Cancer Tumor Profiling Product Introduction
  • 7.8.4 Hologic Gen-Probe Response to COVID-19 and Related Developments
• 7.9 BD Biosciences
  • 7.9.1 BD Biosciences Business Overview
  • 7.9.2 BD Biosciences Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.9.3 BD Biosciences Cancer Tumor Profiling Product Introduction
  • 7.9.4 BD Biosciences Response to COVID-19 and Related Developments
• 7.10 Siemens Healthineers
  • 7.10.1 Siemens Healthineers Business Overview
  • 7.10.2 Siemens Healthineers Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.10.3 Siemens Healthineers Cancer Tumor Profiling Product Introduction
  • 7.10.4 Siemens Healthineers Response to COVID-19 and Related Developments
• 7.11 Claris Life Sciences
  • 7.11.1 Claris Life Sciences Business Overview
  • 7.11.2 Claris Life Sciences Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.11.3 Claris Life Sciences Cancer Tumor Profiling Product Introduction
  • 7.11.4 Claris Life Sciences Response to COVID-19 and Related Developments
• 7.12 Personal Genome Diagnostics, Inc.
  • 7.12.1 Personal Genome Diagnostics, Inc. Business Overview
  • 7.12.2 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.12.3 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Product Introduction
  • 7.12.4 Personal Genome Diagnostics, Inc. Response to COVID-19 and Related Developments
• 7.13 Perthera, Inc.
  • 7.13.1 Perthera, Inc. Business Overview
  • 7.13.2 Perthera, Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.13.3 Perthera, Inc. Cancer Tumor Profiling Product Introduction
  • 7.13.4 Perthera, Inc. Response to COVID-19 and Related Developments
• 7.14 Foundation Medicine, Inc
  • 7.14.1 Foundation Medicine, Inc Business Overview
  • 7.14.2 Foundation Medicine, Inc Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.14.3 Foundation Medicine, Inc Cancer Tumor Profiling Product Introduction
  • 7.14.4 Foundation Medicine, Inc Response to COVID-19 and Related Developments
• 7.15 V., Strand
  • 7.15.1 V., Strand Business Overview
  • 7.15.2 V., Strand Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.15.3 V., Strand Cancer Tumor Profiling Product Introduction
  • 7.15.4 V., Strand Response to COVID-19 and Related Developments
• 7.16 ApoCell
  • 7.16.1 ApoCell Business Overview
  • 7.16.2 ApoCell Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.16.3 ApoCell Cancer Tumor Profiling Product Introduction
  • 7.16.4 ApoCell Response to COVID-19 and Related Developments
• 7.17 Contextual Genomics
  • 7.17.1 Contextual Genomics Business Overview
  • 7.17.2 Contextual Genomics Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.17.3 Contextual Genomics Cancer Tumor Profiling Product Introduction
  • 7.17.4 Contextual Genomics Response to COVID-19 and Related Developments
• 7.18 Agendia
  • 7.18.1 Agendia Business Overview
  • 7.18.2 Agendia Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.18.3 Agendia Cancer Tumor Profiling Product Introduction
  • 7.18.4 Agendia Response to COVID-19 and Related Developments
• 7.19 GenScript
  • 7.19.1 GenScript Business Overview
  • 7.19.2 GenScript Cancer Tumor Profiling Quarterly Revenue, 2020
  • 7.19.3 GenScript Cancer Tumor Profiling Product Introduction
  • 7.19.4 GenScript Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US